Purchase 3,4-DMMC
Discount program, second order - 5%OFF, third order - 7% OFF
With us securely! - re-shipment guarantees.
We always offer new legal products of impeccable quality.
Please make sure that the product is legal in your country and not under control before ordering.
We do not sell pharmaceutical products or controlled products.
Where to buy 3,4-DMMC for sale
3,4-DMMC is a stimulant drug first reported in 2010 as a designer drug analogue of mephedrone, apparently produced in response to the banning of mephedrone. 3,4-DMMC has been seized as a designer drug in Australia. In vitro, 3,4-DMMC was shown to be a monoamine transporter substrate that potently inhibits norepinephrine and serotonin reuptake and, to a lesser extent, dopamine reuptake.
3,4-DMMC is a stimulant drug first reported in 2010 as a designer drug analogue of mephedrone, apparently produced in response to the banning of mephedrone. 3,4-DMMC has been seized as a designer drug in Australia. In vitro, 3,4-DMMC is a monoamine transporter substrate with serotonin and norepinephrine reuptake inhibition properties and dopamine reuptake inhibition properties to a lesser extent.
3,4-DMMC is a recreational drug that has been shown to have psychoactive effects similar to other stimulant drugs. It has also been shown to inhibit the reuptake of norepinephrine and serotonin.
3,4-DMMC is a stimulant drug first reported in 2010 as a designer drug analogue of mephedrone.
3,4-DMMC is a stimulant drug (drug category: empathogen-entactogen, or "designer amphetamine") with similarities to MDMA.
3,4-DMMC is similar to drugs such as mephedrone but seems to be less popular.
3,4-DMMC is a stimulant drug first reported in 2010 as a designer drug analogue of mephedrone, apparently produced in response to the banning of mephedrone. It has been seized as a designer drug in Australia. In vitro, 3,4-DMMC was shown to be a monoamine transporter substrate that potently inhibits norepinephrine and serotonin reuptake.
3,4-DMMC, also known as 3-methoxymorphinan, is a stimulant drug first reported in 2010 as a designer drug analogue of mephedrone. It has been arrested as a designer drug in Australia. In vitro, 3,4-DMMC was shown to be a monoamine transporter substrate that potently inhibits norepinephrine and serotonin reuptake.
3,4-DMMC is a stimulant drug created in 2010 and reportedly related to mephedrone. It is similar to the cathinone family of compounds, which includes the active constituents of khat, ephedrine, and cathinone. 3,4-DMMC was sold on the Internet as a designer drug and is a monoamine transporter substrate comparable in potency for norepinephrine reuptake to methamphetamine and MDMA. It has been reported that 3,4-DMMC causes eosinophilia in humans and rats in vivo via the activation of an AhR-independent pathway.
3,4-DMMC is a stimulant drug that belongs to the amphetamine class.
3,4-DMMC is a drug of the 4-methyl methcathinone class.
3,4-dimethylmethcathinone (3,4-DMMC) is a stimulant drug first reported in 2010 as a designer drug analogue of mephedrone. 3,4-DMMC is a monoamine transporter substrate that potently inhibits norepinephrine and serotonin reuptake but with low selectivity over dopamine reuptake.
3,4-Dimethylmethcathinone (3,4-DMMC) is a stimulant drug first reported in 2010 as a designer drug analogue of mephedrone. It has been seized as a designer drug in Australia.
3,4-DMMC is a designer drug similar to mephedrone but more potent and has different effects. 3,4-DMMC is a stimulant drug with no known medical use. It has been found in the urine at levels greater than one ng/mL in 14% of subjects who reported using mephedrone.
The effects of 3,4-DMMC are very similar to those of mephedrone. Users report being able to focus and concentrate better. Users report an increase in sociability, energy and self-confidence.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics
100g $510
500g $1080
1kg $1690
1kg $1690
100g $840
out of stock
500g $1080
500g $1080
100g $600
200g $690
out of stock
100g $490